Daré Bioscience Inc (DARE)
NASDAQ:DARE
Want to see DARE full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.45Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call presents a constructive and catalytic picture: multiple near-term commercial milestones (Flora Sync LF5 launch in June, DARE to PLAY dispensing targeted this summer, first product revenue for the company) and positive clinical progress (Ovaprene DSMB review, DARE-HPV IND and Phase II start) are strong positives. These are balanced against material execution and financing risks — limited cash/working capital, need to raise capital absent revenue, state-by-state fulfillment delays and tolerability-related discontinuations in the Ovaprene trial. On net, the multiple commercial and clinical catalysts combined with significant nondilutive grant funding and clear go-to-market plans slightly outweigh the operational and liquidity headwinds.Company Guidance
First Direct Product Revenue Imminent
Flora Sync LF5 commercial launch expected June 2026 with first recorded product revenue in Q2 2026; DARE to PLAY pre-fulfillment prescribing live across 50 states since Feb 2026 and DARE to PLAY product revenue expected in Q3 2026.
Positive Clinical and Regulatory Milestones
Ovaprene Phase III received a second consecutive positive DSMB review; interim pregnancy rate ~9% (consistent with expectations); no new serious device-related adverse events; DARE-HPV IND cleared Feb 2026 and Phase II planned to begin May 2026.
Meaningful Clinical Data and Provider Enthusiasm
DARE to PLAY has clinical data showing increased genital blood flow in 10–15 minutes and improvements in arousal/orgasm/desire; strong clinician interest at ACOG with providers writing prescriptions and requesting in-office stocking — signaling early provider advocacy.
Pipeline Breadth and Dual-Path Commercial Strategy
Company executing a dual-path approach (503B compounding + 505(b)(2) NDA pathway) across multiple programs (DARE to PLAY, DARE to RESTORE/Flora Sync LF5, DARE to RECLAIM, Ovaprene, DARE-HPV and other grant-funded contraceptives), enabling simultaneous market building and regulatory advancement.
Grant Funding and Non-Dilutive Support
Significant nondilutive funding received: 2025 grants included ~$13.6M from Gates, ~$4.5M ARPA-H, ~$1.3M NIH (total ~$19.4M in 2025), plus an additional $2.0M ARPA-H in Feb 2026; contra R&D recognized of ~$3.5M in Q1 2026 (up ~12.9% vs Q1 2025).
R&D Investment Leveraged by Grants
Reported R&D expense of ~$0.7M in Q1 2026 (versus ~$2.3M in Q1 2025) is offset by contra R&D grant recognition (~$3.5M), indicating materially greater total R&D activity than GAAP expense line suggests.
Clinical Enrollment and Progress Toward Primary Endpoint
Ovaprene DSMB reviewed data from 340 subjects contributing nearly 1,800 cycles (~72% of the 2,500-cycle target); company expects to achieve 2,500 cycles in 2026, putting primary endpoint analysis within reach in 2027.
DARE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DARE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $2.86 | $2.17 | -24.13% |
Mar 26, 2026 | $1.51 | $1.55 | +2.65% |
Nov 13, 2025 | $1.89 | $1.86 | -1.59% |
Aug 14, 2025 | $2.07 | $2.20 | +6.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Daré Bioscience Inc (DARE) report earnings?
Daré Bioscience Inc (DARE) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Daré Bioscience Inc (DARE) earnings time?
Daré Bioscience Inc (DARE) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DARE EPS forecast?
DARE EPS forecast for the fiscal quarter 2026 (Q2) is -0.3.